Preclinical News and Research

RSS

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Circuit Therapeutics today announced that it has been awarded a 2.7 million dollar contract from the Defense Advanced Research Projects Agency to pursue optogenetic therapies for peripheral nervous system indications. The award, part of DARPA's Electrical Prescriptions (ElectRX) program, will enable Circuit to pursue research and development projects related to its treatment for neuropathic pain.

10 Dec 2015

NeuroQuest to start U.S. clinical validation trials of blood test for early diagnosis of Alzheimer's disease

NeuroQuest Development Center, Inc., today announced they have entered into a service agreement with the University of California, San Diego for collection and processing of blood samples for their U.S. clinical validation trials.

10 Dec 2015

Ajinomoto Althea expands biological drug product manufacturing operations

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).

10 Dec 2015

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Patients with mild heart failure stand to benefit from a new drug that can halt the progression of their disease and reduce their risk of cardiovascular-related death. But the drug -- a tablet that combines the agents valsartan and sacubitril, sold under the trade name Entresto by drugmaker Novartis -- may be too good to be true, according to Arthur M. Feldman, MD, PhD, Executive Dean of the Lewis Katz School of Medicine at Temple University, Chief Academic Officer of the Temple University Health System, and Laura H. Carnell Professor of Medicine at LKSOM.

10 Dec 2015

Scientists discover that blocking RANKL protein stops osteosarcoma

Scientists at Princess Margaret Cancer Centre have discovered that blocking the master regulator of bone renewal stops osteosarcoma - the most common primary bone cancer in children and teens, and the malignant disease that was fatal for Canadian icon Terry Fox.

10 Dec 2015

Aspirin does not improve survival among breast cancer patients with aggressive disease

Whether aspirin may help prevent or reduce the risk of breast cancer remains a hotly debated research question. While past studies have indicated a potential benefit, most recently in hormone receptor-positive breast cancers, one new study from Penn Medicine suggests otherwise.

9 Dec 2015

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

Australian drug development company Bionomics Limited will launch a key Phase 2 trial of its novel anxiety drug BNC210 as a treatment for post-traumatic stress disorder (PTSD), following a US$12 million private placement to US institutional investors.

8 Dec 2015

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

A new collaborative program between scientists at SRI Biosciences, a division of SRI International, and physician-researchers from Stanford Cancer Institute will pursue development of novel compounds to treat multiple forms of cancer and other conditions.

8 Dec 2015

Existing compound offers hope for slowing Huntington's disease progression

Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.

8 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

Cell Therapy Catapult’s 2015 Annual Review highlights key achievements across UK’s health and economy

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the release of their 2015 Annual Review.

7 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

New combination approach to eradicate established tumors

A laboratory study conducted at Leiden University Medical Center in the Netherlands has found that immunotherapy can be efficiently combined with photodynamic therapy (PDT) to eradicate established tumors. The approach results in strong local tumor destruction and a robust systemic immune response against the disease.

27 Nov 2015

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

In the five decades since camptothecin was first isolated from the bark of a tree used in traditional Chinese medicine and identified as a powerful anticancer agent, several thousand chemicals with similar structures and functions have been investigated. And while two of these analog compounds, irinotecan and topotecan, have been approved in the U.S. as treatments for cancer, both are associated with significant shortcomings.

26 Nov 2015

Key finding aids quest to produce liver cell therapies

Stem cell scientists have made a key find that aids the quest to produce therapies for patients with liver damage.

26 Nov 2015

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years. Researchers from the University and University Hospital Basel have now for the first time successfully combined such an antibody-drug conjugate with a therapy that stimulates the immune system to attack tumor cells.

26 Nov 2015

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Allergan plc, a leading global pharmaceutical company, and Rugen Therapeutics, a start-up biotechnology company focused on the development of novel treatments for unmet CNS disorders and funded by the F-Prime Biomedical Research Initiative, today announced that they have entered into an exclusive collaboration to support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).

25 Nov 2015

Mathematical models may help to predict risk of cancer spread following surgery

The size of a surgically removed tumor is generally thought to relate to the risk of the cancer spreading to other regions of the body. But because tumor cells may metastasize at different times and the rate of spread is difficult to assess, the relationship between tumor size and the relative risk of recurrence after surgery is challenging to calculate.

25 Nov 2015

RPCI-led researchers identify strategies to prevent acute kidney injury

Acute kidney injury (AKI), also known as acute renal failure, is one of the main contributors to death and disability worldwide, yet no preventive treatment for the condition has been established. In a new study published in the journal Cell Death and Differentiation, a team of researchers led by scientists from Roswell Park Cancer Institute reports that they have identified 10 genes whose inhibition appears to protect kidney cells.

25 Nov 2015

Preclinical News and Research

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

NeuroQuest to start U.S. clinical validation trials of blood test for early diagnosis of Alzheimer's disease

Ajinomoto Althea expands biological drug product manufacturing operations

New heart failure drug may increase patients' risk of Alzheimer's disease, macular degeneration

Scientists discover that blocking RANKL protein stops osteosarcoma

Aspirin does not improve survival among breast cancer patients with aggressive disease

Bionomics plans to launch BNC210 Phase 2 trial for treatment of PTSD

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

Existing compound offers hope for slowing Huntington's disease progression

Researchers discover 'triple attack' technique to target liver cancer tumors

Cell Therapy Catapult’s 2015 Annual Review highlights key achievements across UK’s health and economy

Heptares announces strategic drug discovery collaboration with Pfizer

Can-Fite BioPharma reports financial results, provides updates on drug development programs

New combination approach to eradicate established tumors

Novel anticancer agent appears to have greater potency, longer efficacy than irinotecan and topotecan

Key finding aids quest to produce liver cell therapies

Researchers successfully combine antibody-drug conjugate with immunotherapy to attack breast cancer cells

Allergan, Rugen Therapeutics collaborate to discover and develop novel therapies for ASD and OCD

Mathematical models may help to predict risk of cancer spread following surgery

RPCI-led researchers identify strategies to prevent acute kidney injury

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics